Quizartinib is another oral, small molecule FLT3 inhibitor that is FDA-approved in combination with intensive induction chemotherapy and cytarabine consolidation, and maintenance following consolidation in adult patients with newly diagnosed AML that is FLT3-ITD positive [86]. The gene discussed is FLT3; the disease is acute myeloid leukemia.